Table 2 The association between clinicopathologic characters and mutation status of EGFR and KRAS mutation as well as rearrangement of EML4-ALK in 1033 Chinese lung cancer patients.
From: Elderly male smokers with right lung tumors are viable candidates for KRAS mutation screening
EGFR mutateon | EML4-ALK | KRAS mutateon | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total | 512 | 53 | 53 | |||||||||
Sex | ||||||||||||
Male | 215 | 41.99 | 30 | 56.60% | 40 | 75.47% | ||||||
Female | 297 | 58.01 | 23 | 43.40% | 13 | 24.53% | ||||||
Age | F1 | M2 | F1 | M2 | F1 | M2 | ||||||
<30 | 3 | 1.01% | 0 | 0.00% | 0 | 0.00% | 0 | 0.00% | 0 | 0.00% | 0 | 0.00% |
31–40 | 10 | 3.37% | 3 | 1.40% | 2 | 8.70% | 0 | 0.00% | 0 | 0.00% | 1 | 2.50% |
41–50 | 38 | 12.79% | 20 | 9.30% | 4 | 17.39% | 7 | 23.33% | 3 | 23.08% | 2 | 5.00% |
51–60 | 98 | 33.00% | 70 | 32.56% | 10 | 43.48% | 6 | 20.00% | 4 | 30.77% | 15 | 37.50% |
61–70 | 109 | 36.70% | 91 | 42.33% | 6 | 26.09% | 13 | 43.33% | 5 | 38.46% | 15 | 37.50% |
>70 | 39 | 13.13% | 31 | 14.42% | 1 | 4.35% | 4 | 13.33% | 1 | 7.69% | 7 | 17.50% |
Site | ||||||||||||
Left | 115 | 38.72% | 77 | 35.81% | 6 | 26.09% | 8 | 26.66% | 7 | 53.84% | 17 | 42.50% |
Right | 173 | 58.25% | 129 | 60.00% | 16 | 69.57% | 21 | 70.00% | 6 | 46.15% | 23 | 57.50% |
Bilateral | 9 | 3.03% | 9 | 4.19% | 1 | 4.35% | 1 | 3.33% | 0 | 0.00% | 0 | 0.00% |
TNM stage | ||||||||||||
Stage I | 212 | 71.38% | 139 | 64.65% | 17 | 73.91% | 22 | 73.34% | 8 | 61.54% | 26 | 65.00% |
Stage II | 18 | 6.06% | 12 | 5.58% | 1 | 4.35% | 2 | 6.66% | 4 | 30.76% | 5 | 12.50% |
Stage III | 50 | 16.84% | 52 | 24.91% | 5 | 21.74% | 6 | 20.00% | 1 | 7.69% | 9 | 22.50% |
Stage IV | 17 | 5.72% | 12 | 5.58% | 1 | 4.35% | 1 | 3.33% | 0 | 0.00% | 3 | 7.50% |
Smoking | ||||||||||||
Never smoker | 275 | 92.59% | 102 | 47.44% | 22 | 95.65% | 16 | 53.33% | 12 | 92.31% | 7 | 17.50% |
<100 | 2 | 0.67% | 1 | 0.47% | 0 | 0.00% | 1 | 3.33% | 0 | 0.00% | 0 | 0.00% |
101–500 | 16 | 5.39% | 53 | 24.65% | 1 | 4.35% | 7 | 23.33% | 1 | 7.69% | 9 | 22.50% |
501–1000 | 4 | 1.35% | 48 | 22.33% | 0 | 0.00% | 5 | 16.67% | 0 | 0.00% | 20 | 50.00% |
>1000 | 0 | 0.00% | 11 | 5.12% | 0 | 0.00% | 1 | 3.33% | 0 | 0.00% | 4 | 10.00% |
Tumor size | ||||||||||||
1–10 | 47 | 15.82% | 25 | 11.63% | 4 | 17.39% | 3 | 10.00% | 1 | 7.69% | 4 | 10.00% |
11–20 | 95 | 31.99% | 65 | 30.23% | 4 | 17.39% | 11 | 36.67% | 3 | 23.08% | 9 | 22.50% |
21–30 | 97 | 32.66% | 73 | 33.95% | 9 | 39.13% | 7 | 23.33% | 1 | 7.69% | 12 | 30.00% |
31–40 | 40 | 13.47% | 31 | 14.42% | 3 | 13.04% | 2 | 6.67% | 4 | 30.77% | 3 | 7.50% |
41–50 | 8 | 2.69% | 7 | 3.26% | 1 | 4.35% | 2 | 6.67% | 0 | 0.00% | 5 | 12.50% |
51–60 | 8 | 2.69% | 6 | 2.79% | 0 | 0.00% | 3 | 10.00% | 2 | 15.38% | 5 | 12.50% |
61–70 | 0 | 0.00% | 2 | 0.93% | 2 | 8.70% | 0 | 0.00% | 0 | 0.00% | 2 | 5.00% |
71–80 | 1 | 0.34% | 4 | 1.86% | 0 | 0.00% | 2 | 6.67% | 0 | 0.00% | 0 | 0.00% |
81–90 | 0 | 0.00% | 1 | 0.47% | 0 | 0.00% | 0 | 0.00% | 1 | 7.69% | 0 | 0.00% |
91–100 | 1 | 0.34% | 0 | 0.00% | 0 | 0.00% | 0 | 0.00% | 1 | 7.69% | 0 | 0.00% |
>100 | 0 | 0.00% | 1 | 0.47% | 0 | 0.00% | 0 | 0.00% | 0 | 0.00% | 0 | 0.00% |
Pathological type | ||||||||||||
Lung adenocarcinomas | 289 | 97.31% | 190 | 88.37% | 23 | 100.00% | 21 | 70.00% | 13 | 100.00% | 32 | 80.00% |
Squamous carcinoma | 0 | 0.00% | 11 | 5.12% | 0 | 0.00% | 7 | 23.33% | 0 | 0.00% | 4 | 10.00% |
Large cell carcinoma | 0 | 0.00% | 5 | 2.33% | 0 | 0.00% | 1 | 3.33% | 0 | 0.00% | 1 | 2.50% |
Small cell carcinoma | 0 | 0.00% | 3 | 1.40% | 0 | 0.00% | 0 | 0.00% | 0 | 0.00% | 0 | 0.00% |
Other | 8 | 2.69% | 6 | 2.79% | 0 | 0.00% | 1 | 3.33% | 0 | 0.00% | 3 | 7.50% |
Visceral pleura Invasion | ||||||||||||
Yes | 129 | 43.43% | 89 | 41.40% | 11 | 47.83% | 17 | 56.67% | 6 | 46.15% | 13 | 32.50% |
No | 168 | 56.57% | 126 | 58.60% | 12 | 52.17% | 13 | 43.33% | 7 | 53.85% | 27 | 67.50% |
